CL2011003046A1 - Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08). - Google Patents
Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08).Info
- Publication number
- CL2011003046A1 CL2011003046A1 CL2011003046A CL2011003046A CL2011003046A1 CL 2011003046 A1 CL2011003046 A1 CL 2011003046A1 CL 2011003046 A CL2011003046 A CL 2011003046A CL 2011003046 A CL2011003046 A CL 2011003046A CL 2011003046 A1 CL2011003046 A1 CL 2011003046A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- sbe7
- benzodiazepine
- pyrrol
- div
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Composición farmacéutica capaz de ser reconstituida con agua a una solución para administración inyectable, que comprende a un derivado de benzodiazepina sustituida; proceso de preparación de dicha composición; y uso para tratar el cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94751207P | 2007-07-02 | 2007-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011003046A1 true CL2011003046A1 (es) | 2012-08-24 |
Family
ID=39737054
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001848A CL2008001848A1 (es) | 2007-07-02 | 2008-06-20 | Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal. |
CL2011003046A CL2011003046A1 (es) | 2007-07-02 | 2011-12-02 | Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08). |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001848A CL2008001848A1 (es) | 2007-07-02 | 2008-06-20 | Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal. |
Country Status (23)
Country | Link |
---|---|
US (2) | US8318713B2 (es) |
EP (1) | EP2173348B1 (es) |
JP (2) | JP5551589B2 (es) |
KR (1) | KR101230085B1 (es) |
CN (2) | CN102772416A (es) |
AR (1) | AR067112A1 (es) |
AU (1) | AU2008270732B2 (es) |
BR (1) | BRPI0813789A2 (es) |
CA (1) | CA2691587C (es) |
CL (2) | CL2008001848A1 (es) |
EA (2) | EA023697B1 (es) |
ES (1) | ES2561202T3 (es) |
HK (1) | HK1141236A1 (es) |
IL (2) | IL202237A (es) |
MA (1) | MA31677B1 (es) |
MX (1) | MX2009013449A (es) |
MY (1) | MY154472A (es) |
NZ (1) | NZ581355A (es) |
PE (1) | PE20090838A1 (es) |
TW (1) | TWI428132B (es) |
UA (1) | UA97400C2 (es) |
WO (1) | WO2009006043A2 (es) |
ZA (1) | ZA200908725B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
PE20120772A1 (es) * | 2009-04-14 | 2012-06-27 | Lilly Co Eli | Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia |
JP2014531456A (ja) * | 2011-09-22 | 2014-11-27 | バインド セラピューティックス インコーポレイテッド | 治療用ナノ粒子と癌を治療する方法 |
TW201417817A (zh) * | 2012-09-25 | 2014-05-16 | Daiichi Sankyo Co Ltd | Gsk3抑制劑與抗dr5抗體之組合 |
WO2016175324A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
US10213511B2 (en) * | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US10016507B2 (en) * | 2016-03-02 | 2018-07-10 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
CN110392686A (zh) | 2016-12-30 | 2019-10-29 | 频率治疗公司 | 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 |
US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
CN113956157B (zh) * | 2021-11-18 | 2024-05-03 | 西安都创医药科技有限公司 | 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP1788086A1 (en) * | 1997-03-17 | 2007-05-23 | Human Genome Sciences, Inc. | Death Domain Containing Receptor 5 |
US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
JP4414232B2 (ja) * | 2002-03-05 | 2010-02-10 | イーライ リリー アンド カンパニー | キナーゼ阻害物質 |
EP1539756B1 (en) | 2002-09-19 | 2007-11-14 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
CA2569091A1 (en) * | 2004-07-09 | 2006-01-19 | Agency For Science, Technology And Research | Modulation of gsk-3.beta. and method of treating proliferative disorders |
GB0418328D0 (en) * | 2004-08-17 | 2004-09-22 | Imp College Innovations Ltd | Cancer methods and medicaments |
US20060252082A1 (en) * | 2005-05-04 | 2006-11-09 | University Of South Florida | Predicting treatment response in cancer subjects |
TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
-
2008
- 2008-06-18 TW TW097122720A patent/TWI428132B/zh not_active IP Right Cessation
- 2008-06-19 PE PE2008001054A patent/PE20090838A1/es not_active Application Discontinuation
- 2008-06-20 AU AU2008270732A patent/AU2008270732B2/en not_active Ceased
- 2008-06-20 WO PCT/US2008/067614 patent/WO2009006043A2/en active Application Filing
- 2008-06-20 KR KR1020097027543A patent/KR101230085B1/ko not_active IP Right Cessation
- 2008-06-20 MY MYPI20095640A patent/MY154472A/en unknown
- 2008-06-20 UA UAA200913938A patent/UA97400C2/uk unknown
- 2008-06-20 NZ NZ581355A patent/NZ581355A/en not_active IP Right Cessation
- 2008-06-20 CN CN2012101150238A patent/CN102772416A/zh active Pending
- 2008-06-20 MX MX2009013449A patent/MX2009013449A/es active IP Right Grant
- 2008-06-20 CA CA2691587A patent/CA2691587C/en not_active Expired - Fee Related
- 2008-06-20 EA EA201201155A patent/EA023697B1/ru not_active IP Right Cessation
- 2008-06-20 CL CL2008001848A patent/CL2008001848A1/es unknown
- 2008-06-20 AR ARP080102668A patent/AR067112A1/es unknown
- 2008-06-20 CN CN2008800231969A patent/CN101743005B/zh not_active Expired - Fee Related
- 2008-06-20 US US12/664,664 patent/US8318713B2/en not_active Expired - Fee Related
- 2008-06-20 BR BRPI0813789-7A2A patent/BRPI0813789A2/pt not_active IP Right Cessation
- 2008-06-20 EA EA201070085A patent/EA018447B1/ru not_active IP Right Cessation
- 2008-06-20 JP JP2010514996A patent/JP5551589B2/ja not_active Expired - Fee Related
- 2008-06-20 EP EP08771559.5A patent/EP2173348B1/en active Active
- 2008-06-20 ES ES08771559.5T patent/ES2561202T3/es active Active
-
2009
- 2009-11-19 IL IL202237A patent/IL202237A/en not_active IP Right Cessation
- 2009-12-08 ZA ZA2009/08725A patent/ZA200908725B/en unknown
-
2010
- 2010-01-27 MA MA32562A patent/MA31677B1/fr unknown
- 2010-08-13 HK HK10107721.9A patent/HK1141236A1/xx not_active IP Right Cessation
-
2011
- 2011-12-02 CL CL2011003046A patent/CL2011003046A1/es unknown
-
2012
- 2012-03-01 IL IL218443A patent/IL218443A0/en unknown
- 2012-10-18 US US13/654,884 patent/US8648063B2/en not_active Expired - Fee Related
-
2014
- 2014-01-17 JP JP2014006560A patent/JP2014114297A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011003046A1 (es) | Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08). | |
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
CL2008002139A1 (es) | Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer. | |
CU20130069A7 (es) | Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis | |
CL2008002687A1 (es) | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
GT200900328A (es) | Derivados de bencimidazol | |
CL2012003227A1 (es) | Compuestos macrociclicos que comprenden en el ciclo una porcion pirazolo[1,5-a]pirimidina, inhibidores de quinasa trk; composicion farmaceutica; proceso de preparación; y metodo para tratar un trastorno seleccionado de dolor, cancer, inflamacion, enfermedad neurodegenerativa o infeccion por trypanosoma cruzi. | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
CU20090103A7 (es) | Derivados de 2,3-dihidroimidazol[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
BR112013002112A2 (pt) | composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição | |
CL2008003393A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina, moduladores alostericos de los receptores de mglur2; composicion farmaceutica que comprende a dichos compuestos; y su uso en la preparacion de medicamentos para tratar trastornos del sistema nervioso central. | |
BRPI0810064B8 (pt) | compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos | |
CL2007001427A1 (es) | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po | |
CL2011000729A1 (es) | Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
CL2011000710A1 (es) | Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer. | |
HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
EA201171243A1 (ru) | Производное бензодиазепина для лечения гематопоэтических новообразований и лейкоза | |
CL2010001488A1 (es) | Proceso para preparar 2,4-dioxo-1,2,4-tetrahidropirido[2,3-d]pirimidin-7-il-fenil sustituido y 2,4-bis[3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il-fenil-sustituido; sal fumarato de {5-[2,4-bis[(3s)-3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il]-2-metoxifenil}metanol; composicon farmaceutica; y uso para tratar el cancer. | |
CL2012001027A1 (es) | Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek. | |
CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
AR054806A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno |